Search Results - "OSHITA, Chie"

Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial by OSHITA, CHIE, TAKIKAWA, MASAKO, KUME, AKIKO, MIYATA, HARUO, ASHIZAWA, TADASHI, IIZUKA, AKIRA, KIYOHARA, YOSHIO, YOSHIKAWA, SHUSUKE, TANOSAKI, RYUJI, YAMAZAKI, NAOYA, YAMAMOTO, AKIFUMI, TAKESAKO, KAZUTOH, YAMAGUCHI, KEN, AKIYAMA, YASUTO

“…Metastatic and chemoresistant melanoma can be a good target of immunotherapy because it is an intractable cancer with a very poor prognosis. Previously, we…”
Get full text

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma by ASHIZAWA, TADASHI, MIYATA, HARUO, IIZUKA, AKIRA, KOMIYAMA, MASARU, OSHITA, CHIE, KUME, AKIKO, NOGAMI, MASAHIRO, YAGOTO, MIKA, ITO, ICHIRO, OISHI, TAKUMA, WATANABE, REIKO, MITSUYA, KOICHI, MATSUNO, KENJI, FURUYA, TOSHIO, OKAWARA, TADASHI, OTSUKA, MASAMI, OGO, NAOHISA, ASAI, AKIRA, NAKASU, YOKO, YAMAGUCHI, KEN, AKIYAMA, YASUTO

“…Signal transducer and activator of transcription (STAT) 3, a member of a family of DNA-binding molecules, is a potential target in the treatment of cancer. The…”
Get full text

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial by Akiyama, Yasuto, Oshita, Chie, Kume, Akiko, Iizuka, Akira, Miyata, Haruo, Komiyama, Masaru, Ashizawa, Tadashi, Yagoto, Mika, Abe, Yoshiaki, Mitsuya, Koichi, Watanabe, Reiko, Sugino, Takashi, Yamaguchi, Ken, Nakasu, Yoko

“…High-grade gliomas including glioblastoma multiforme (GBM) are among the most malignant and aggressive of tumors, and have a very poor prognosis despite a…”
Get full text

Identification of a New Series of STAT3 Inhibitors by Virtual Screening by Matsuno, Kenji, Masuda, Yoshiaki, Uehara, Yutaka, Sato, Hiroshi, Muroya, Ayumu, Takahashi, Osamu, Yokotagawa, Takane, Furuya, Toshio, Okawara, Tadashi, Otsuka, Masami, Ogo, Naohisa, Ashizawa, Tadashi, Oshita, Chie, Tai, Sachiko, Ishii, Hidee, Akiyama, Yasuto, Asai, Akira

“…The signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for oncology drug development. We…”
Get full text

YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line by AKIYAMA, YASUTO, ASHIZAWA, TADASHI, KOMIYAMA, MASARU, MIYATA, HARUO, OSHITA, CHIE, OMIYA, MAHO, IIZUKA, AKIRA, KUME, AKIKO, SUGINO, TAKASHI, HAYASHI, NAKAMASA, MITSUYA, KOICHI, NAKASU, YOKO, YAMAGUCHI, KEN

“…The frequent recurrence of glioblastoma multiforme (GBM) after standard treatment with temozolomide (TMZ) is a crucial issue to be solved in the clinical…”
Get full text

Analysis of HLA‐A24‐restricted peptides of carcinoembryonic antigen using a novel structure‐based peptide‐HLA docking algorithm by Nakamura, Yoji, Tai, Sachiko, Oshita, Chie, Iizuka, Akira, Ashizawa, Tadashi, Saito, Shuji, Yamaguchi, Shigeki, Kondo, Haruhiko, Yamaguchi, Ken, Akiyama, Yasuto

“…Carcinoembryonic antigen (CEA) is a very common tumor marker because many types of solid cancer usually produce a variety of CEA and a highly sensitive…”
Get full text

Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning by Iizuka, Akira, Komiyama, Masaru, Oshita, Chie, Kume, Akiko, Ashizawa, Tadashi, Mitsuya, Koichi, Hayashi, Nakamasa, Nakasu, Yoko, Yamaguchi, Ken, Akiyama, Yasuto

“…Highlights • Single B cell-based human monoclonal antibody gene PCR cloning method was developed. • Plasma autoantibodies against VEGFR2 antigen were detected…”
Get full text

Identification of cytomegalovirus (CMV)pp65 antigen-specific human monoclonal antibodies using single B cell-based antibody gene cloning from melanoma patients by Iizuka, Akira, Komiyama, Masaru, Tai, Sachiko, Oshita, Chie, Kurusu, Ayumi, Kume, Akiko, Ozawa, Kazumichi, Nakamura, Yoji, Ashizawa, Tadashi, Yamamoto, Akifumi, Yamazaki, Naoya, Yoshikawa, Shusuke, Kiyohara, Yoshio, Yamaguchi, Ken, Akiyama, Yasuto

“…Abstract Recently, because of highly advanced protein engineering technology, beyond the chimeric antibody, highly humanized and fully human antibody…”
Get full text

The identification of affinity peptide ligands specific to the variable region of human antibodies by Akiyama, Yasuto, Miyata, Haruo, Komiyama, Masaru, Nogami, Masahiro, Ozawa, Kazumichi, Oshita, Chie, Kume, Akiko, Ashizawa, Tadashi, Sakura, Naoki, Mochizuki, Tohru, Yamaguchi, Ken

“…Of all potential biological therapeutics, monoclonal antibody (mAb)-based therapies are becoming the dominant focus of clinical research. In particular,…”
Get full text

Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients by AKIYAMA, YASUTO, KOMIYAMA, MASARU, MIYATA, HARUO, YAGOTO, MIKA, ASHIZAWA, TADASHI, IIZUKA, AKIRA, OSHITA, CHIE, KUME, AKIKO, NOGAMI, MASAHIRO, ITO, ICHIRO, WATANABE, REIKO, SUGINO, TAKASHI, MITSUYA, KOICHI, HAYASHI, NAKAMASA, NAKASU, YOKO, YAMAGUCHI, KEN

Get full text

The identification of affinity peptide ligands specific to the variable region ofhuman antibodies by AKIYAMA, Yasuto, MIYATA, Haruo, KOMIYAMA, Masaru, NOGAMI, Masahiro, OZAWA, Kazumichi, OSHITA, Chie, KUME, Akiko, ASHIZAWA, Tadashi, SAKURA, Naoki, MOCHIZUKI, Tohru, YAMAGUCHI, Ken

“…Of all potential biological therapeutics, monoclonal antibody (mAb)-based therapies are becomingthe dominant focus of clinical research. In particular, smaller…”
Get full text

Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation by ASHIZAWA, Tadashi, MIYATA, Haruo, ASAI, Akira, AKIYAMA, Yasuto, ISHII, Hidee, OSHITA, Chie, MATSUNO, Kenji, MASUDA, Yoshiaki, FURUYA, Toshio, OKAWARA, Tadashi, OTSUKA, Masami, OGO, Naohisa

“…Signal transducer and activator of transcription (STAT)3, a member of a family of DNA-binding molecules mediating numerous physiological and oncogenic…”
Get full text

Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients by AKIYAMA, YASUTO, KOMIYAMA, MASARU, MIYATA, HARUO, YAGOTO, MIKA, ASHIZAWA, TADASHI, IIZUKA, AKIRA, OSHITA, CHIE, KUME, AKIKO, NOGAMI, MASAHIRO, ITO, ICHIRO, WATANABE, REIKO, SUGINO, TAKASHI, MITSUYA, KOICHI, HAYASHI, NAKAMASA, NAKASU, YOKO, YAMAGUCHI, KEN

“…Glioblastoma multiforme (GBM) is one of the most malignant and aggressive tumors, and has a very poor prognosis with a mean survival time of <2 years, despite…”
Get full text

Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay by Akiyama, Yasuto, Komiyama, Masaru, Nakamura, Yoji, Iizuka, Akira, Oshita, Chie, Kume, Akiko, Nogami, Masahiro, Miyata, Haruo, Ashizawa, Tadashi, Yoshikawa, Shusuke, Kiyohara, Yoshio, Yamaguchi, Ken

“…Many cancer-testis antigen genes have been identified; however, few human leukocyte antigen (HLA)-A24-restricted cytotoxic T cell (CTL) epitope peptides are…”
Get full text

type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial by Akiyama, Yasuto, Oshita, Chie, Kume, Akiko, Iizuka, Akira, Miyata, Haruo, Komiyama, Masaru, Ashizawa, Tadashi, Yagoto, Mika, Abe, Yoshiaki, Mitsuya, Koichi, Watanabe, Reiko, Sugino, Takashi, Yamaguchi, Ken, Nakasu, Yoko

“…Background High-grade gliomas including glioblastoma multiforme (GBM) are among the most malignant and aggressive of tumors, and have a very poor prognosis…”
Get full text

Analysis of HLA‐A24‐restricted peptides of carcinoembryonic antigen using a novel structure‐based peptide‐HLA docking algorithm by Nakamura, Yoji, Tai, Sachiko, Oshita, Chie, Iizuka, Akira, Ashizawa, Tadashi, Saito, Shuji, Yamaguchi, Shigeki, Kondo, Haruhiko, Yamaguchi, Ken, Akiyama, Yasuto

Get full text